NCT02145741 - Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 11, 2014

Primary Completion Date

July 1, 2015

Study Completion Date

July 14, 2023

Conditions

Neoplasms

Interventions

DRUG

750 milligram Xentuzumab

750 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.

DRUG

1000 milligram Xentuzumab

1000 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.

DRUG

1400 milligram Xentuzumab

1400 milligram Xentuzumab given weekly (days 1, 8, and 15) as an intravenous infusion over 1 hour. Patients stayed on treatment in 21-day cycles until disease progression or undue toxicities.

Trial Locations (1)

277-8577

National Cancer Center Hospital East, Chiba, Kashiwa